FierceBiotech Dec 9, 2025 Pfizer continues renewed obesity push with $150M upfront for Fosun unit's GLP-1 drug
FierceBiotech Dec 9, 2025 ASH: Exicure rebounds with phase 2 win, seeing 90% blood cell mobilization in myeloma
FierceBiotech Dec 9, 2025 Novartis pens $1.7B immuno-dermatology pact with AI-enabled British biotech
FierceBiotech Dec 9, 2025 FDA steers cancer CAR-T developers toward randomized superiority trials in policy shift
FierceBiotech Dec 9, 2025 ASH: Merck mulls future of polycythemia program while Takeda takes phase 3 victory lap
FierceBiotech Dec 8, 2025 With weight loss windfall, Lilly looks to become ‘backbone’ of global innovation: exec
FierceBiotech Dec 8, 2025 Dr. Reddy's pens $370M pact for rights to Immutep's phase 3-stage immunotherapy in certain markets
FierceBiotech Dec 8, 2025 AbbVie hands back phase 1 duties for chronic inflammation drug to partner OSE
FierceBiotech Dec 7, 2025 ASH: Anito-cel strengthens best-in-class potential as Gilead's Kite preps for launch
FierceBiotech Dec 7, 2025 ASH: Star antibody sparkles in preview of potential phase 3 bleeding disease success
FierceBiotech Dec 6, 2025 ‘Market’s thinking is backwards’: FDA’s 1-trial approval plan would boost R&D spend, Jefferies says